Individual Study / SPARK-CPPQ

Centre for Precision Psychiatry - Quebec
  1. Home
  2. Individual Studies
  3. SPARK-CPPQ

Centre for Precision Psychiatry - Quebec

SPARK-CPPQ logo
Networks -
Datasets -
Variables -
Start Year
2022
Supplementary Information
The CPPQ platform offers unique value by combining comprehensive clinical and biological data, enabling researchers to study the complex interactions driving psychiatric disorders. Its transdiagnostic design allows for research beyond traditional categorical diagnoses, and the extended 10-year follow-up period provides insights into long-term clinical outcomes that are not available in existing datasets.
Visit SPARK-CPPQ
Add to cart

Members

Download
Investigators Contacts
  • Dr. Simon Ducharme
    Douglas Research Centre, McGill university
  • Dr. Anne Almey
    Centre for Precision Psychiatry
  • Dr. Sophie Blais-Michaud
    Centre for Precision Psychiatry

Design

Study design
Cohort
Follow Up
After baseline, participants are seen at year 2, 5 and 10 years. Data on Psychiatric patients is also collected every six months.

Recruitment

Recruitment Target
  • Individuals

Number of Participants

Number of Participants
150
Number of Participants with Biological Samples
150
Supplementary Information
The study aims to recruit 1000 participants.

Access

Availability of data and biosamples

Possible Access to Data
Possible Access to Biosamples
Other

Availability of access information

On the study website : https://www.cppquebec.ca

By contacting the study representative

Sector of research

Possible Access to Data Possible Access to Biosamples
Investigators from the public sector
Investigators from the private sector
Investigators from not-for-profit organization

The research proposed must be presented by an academic investigator. Private research groups will require an academic principal investigator be associated with the project.

Transfer

Possible Access to Data Possible Access to Biosamples
Can leave the study facility
Can leave the country

a Material/Data Transfer Agreement (MDTA) is required prior to releasing the material/data. This document defines the way that the data will be used, who will have access to the data, how the data will be stored, and stipulates that researchers will not attempt to determine the identity of any participants] (e.g. anonymization, encryption, double coding, etc.

Cost

Possible Access to Data Variable Cost
Possible Access to Biosamples Variable Cost

The CPPQ will provide cost-free access to renewable data (clinical, cognitive, lifestyle, neuroimaging, and results of biological analyses including genetics, transcriptomics, etc.) for academic research groups. Research groups from industry will need to pay for access to this renewable data. In contrast, a fee will be associated with access to nonrenewable biological material for research groups from both academic and industry. The CPPQ will specify the cost to the research teams from both academia and industry when approving access to material/data from the CPPQ. All fees for academic researchers will be based on cost recovery and will not derive profit for the CPPQ.

Cost reduction for co-analyses

Possible Access to Data
Possible Access to Biosamples

Depend on the context, would be assessed by the Access committee.

Yes
No
Not applicable
Don't know

Timeline

Populations

Selection Criteria
Minimum age
18
Maximum age
65
Newborns
Twins
Countries
  • Canada
Territory
Ethnic Origin
Health Status
  • Participants with intellectual disabilities, neurocognitive disorders (e.g., dementia, Alzheimer’s disease, Parkinson’s disease), neurobiological diseases (e.g., multiple sclerosis, epilepsy), or diseases that significantly impact endocrine function (e.g., Cushing's disease, Hashimoto’s disease) are excluded.
Other Criteria

Recruitment

Sources of recruitment
  • Specific population
Specific Population
  • Clinic patients
Supplementary Information
Participants are recruited from two psychiatric hospitals, the Douglas Institute and the Montreal General Hospital, on a voluntary basis.

Number of Participants

Number of Participants
141
Number of Participants with Biological Samples
141
Data Collection Events
# Name Description Start End
0 SPARK-CPPQ - Baseline Participants complete a series of questionnaires through the Brain Health Initiative Platform (BHOP) developed at McGill University. Demographics and physical activity measures which consist of ... 2022-01 2032
1 SPARK-CPPQ - 6 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2022-07 2032
2 SPARK-CPPQ - 12 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2023-01 2032
3 SPARK-CPPQ - 18 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2023-07 2032
4 SPARK-CPPQ - 2 years follow-up Participants complete a series of questionnaires through the Brain Health Initiative Platform (BHOP) developed at McGill University. Demographics and physical activity measures which consist of ... 2024 2032
5 SPARK-CPPQ - 30 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2024-07 2032
6 SPARK-CPPQ - 36 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2025-01 2032
7 SPARK-CPPQ - 42 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2025-07 2032
8 SPARK-CPPQ - 48 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2026-01 2032
9 SPARK-CPPQ - 54 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2026-07 2032
10 SPARK-CPPQ - 5 years follow-up Participants complete a series of questionnaires through the Brain Health Initiative Platform (BHOP) developed at McGill University. Demographics and physical activity measures which consist of ... 2027 2035
11 SPARK-CPPQ - 66 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2027-07 2032
12 SPARK-CPPQ - 72 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2028-01 2032
13 SPARK-CPPQ - 78 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2028-07 2032
14 SPARK-CPPQ - 84 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2029-01 2032
15 SPARK-CPPQ - 90 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2029-07 2032
16 SPARK-CPPQ - 96 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2030-01 2032
17 SPARK-CPPQ - 102 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2030-07 2032
18 SPARK-CPPQ - 108 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2031-01 2032
19 SPARK-CPPQ - 114 months follow-up Overall severity of a participant's psychiatric illness (CGI-S), degree of improvement or deterioration in psychiatric condition (CGI-I) and list treatments that have been the most helpful over ... 2031-07 2032
20 SPARK-CPPQ - 10 years follow-up Participants complete a series of questionnaires through the Brain Health Initiative Platform (BHOP) developed at McGill University. Demographics and physical activity measures which consist of ... 2032 2032
Selection Criteria
Minimum age
18
Maximum age
65
Newborns
Twins
Countries
  • Canada
Territory
Ethnic Origin
Health Status

Recruitment

Sources of recruitment
  • General population
General Population
  • Volunteer enrolment
Supplementary Information
Participants were recruited through social media advertisements and by distributing pamphlets to current patients, who then shared them with their relatives.

Number of Participants

Number of Participants
9
Number of Participants with Biological Samples
9
Data Collection Events
# Name Description Start End
0 SPARK-CPPQ - Baseline Participants complete a series of questionnaires through the Brain Health Initiative Platform (BHOP) developed at McGill University. Demographics and physical activity measures which consist of ... 2022 2032
4 SPARK-CPPQ - 2 year follow-up Participants complete a series of questionnaires through the Brain Health Initiative Platform (BHOP) developed at McGill University. Demographics and physical activity measures which consist of ... 2024 2032
10 SPARK-CPPQ - 5 years follow-ups Participants complete a series of questionnaires through the Brain Health Initiative Platform (BHOP) developed at McGill University. Demographics and physical activity measures which consist of ... 2027 2032
20 SPARK-CPPQ - 10 years follow-up Participants complete a series of questionnaires through the Brain Health Initiative Platform (BHOP) developed at McGill University. Demographics and physical activity measures which consist of ... 2032 2032

Classifications

Socio-demographic and economic characteristics
Lifestyle and behaviours
Birth, pregnancy and reproductive health history
Perception of health, quality of life, development and functional limitations
Diseases
Symptoms and signs
Medication and supplements
Non-pharmacological interventions
Health and community care services utilization
Death
Physical measures and assessments
Laboratory measures
Cognition, personality and psychological measures and assessments
Life events, life plans, beliefs and values
Preschool, school and work life
Social environment and relationships
Physical environment
Administrative information
Cognitive functioning
Personality
Psychological distress and emotions
Other psychological measures and assessments
Life events
Beliefs and values
Perception of health
Quality of life
Life course development
Functional limitations
Other perception of health, quality of life and functional limitation-related information
Tobacco
Alcohol
Drugs
Nutrition
Breastfeeding
Physical activity
Sleep
Sexual behaviours and orientation
Technological devices
Misbehaviour and criminality
Other and unspecified lifestyle information

Socio-demographic and economic characteristics

Age/birthdate
Sex/gender
Family and household structure
Education
Citizenship and immigrant status
Ethnicity, race and religion
Labour force and retirement
Other socio-demographic and economic characteristics

Lifestyle and behaviours

Tobacco
Alcohol
Drugs
Nutrition
Physical activity
Sleep
Sexual behaviours and orientation
Other and unspecified lifestyle information

Perception of health, quality of life, development and functional limitations

Perception of health
Quality of life
Life course development
Functional limitations

Diseases

Certain infectious and parasitic diseases (A00-B99)
Neoplasms (C00-D48)
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89)
Endocrine, nutritional and metabolic diseases (E00-E90)
Mental and behavioural disorders (F00-F99)
Diseases of the nervous system (G00-G99)
Diseases of the eye and adnexa (H00-H59)
Diseases of the ear and mastoid process (H60-H95)
Diseases of the circulatory system (I00-I99)
Diseases of the respiratory system (J00-J99)
Diseases of the digestive system (K00-K93)
Diseases of the musculoskeletal system and connective tissue (M00-M99)
Diseases of the genitourinary system (N00-N99)
Pregnancy, childbirth and the puerperium (O00-O9A)
Congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)
Injury, poisoning and certain other consequences of external causes (S00-T98)
External causes of morbidity and mortality (V01-Y98)
Diseases without precise specification or falling into multiple categories

Symptoms and signs

Symptoms and signs involving the circulatory and respiratory systems (R00-R09)
Symptoms and signs involving the digestive system and abdomen (R10-R19)
Symptoms and signs involving nervous and musculoskeletal systems (R25-R29)
Symptoms and signs involving the urinary system (R30-R39)
Symptoms and signs involving cognition, perception, emotional state and behaviour (R40-R46)
General symptoms and signs (R50-R69)
Symptoms related to multiple categories

Medication and supplements

Medication and supplement intake
Posology and protocol of administration

Non-pharmacological interventions

Surgical interventions
Radiological interventions
Cognitive, psychological and sensory interventions
Laboratory diagnosis interventions
Other and unspecified non-pharmacological interventions

Health and community care services utilization

Visits to health professionals

Death

Vital status
Cause of death

Physical measures and assessments

Other physical measures and assessments

Laboratory measures

Biochemistry

Cognition, personality and psychological measures and assessments

Cognitive functioning
Personality
Psychological distress and emotions

Life events, life plans, beliefs and values

Life events

Preschool, school and work life

School life

Social environment and relationships

Other social environment characteristics

Administrative information

Date and time-related information
Physical and cognitive measure and biosample-related information
Other administrative information

Cognitive functioning

Wechsler Adult Intelligence Scale (Coding)
Wechsler Adult Intelligence Scale (Matrix Reasoning)
Wechsler Memory Scale (Face recognition)
Wechsler Memory Scale (Verbal Paired Associates)

Personality

Ten-Item Personality Inventory

Psychological distress and emotions

Goldberg Anxiety and Depression Scales (Anxiety)
Hamilton Depression Rating Scale
Mini International Neuropsychiatric Interview
Patient Health Questionnaire

Life events

Childhood Experiences of Violence Questionnaire

Beliefs and values

Age-group Identification Scale

Perception of health

Communicating Cognitive Concerns Questionnaire

Quality of life

EuroQol Five Dimensions Questionnaire
Preference‑Based Multiple Sclerosis Index
PROMIS Ability to Participate in Social Roles and Activities
PROMIS Physical Function
Short-Form 36 Health Survey
Sheehan Disability Scale
Transgender Congruence Scale

Life course development

Adult ADHD Self-Report Scale

Functional limitations

Older Americans Resources and Services Multidimensional Functional Assessment Questionnaire
Patient-Reported Outcomes Measurement Information System (Physical function)

Tobacco

Fagerström Test for Nicotine Dependence

Alcohol

Alcohol Use Disorders Identification Test

Drugs

Cannabis Use Disorders Identification Test
Drug abuse screening test

Sleep

Athens Insomnia Scale